Market capitalization | $73.41m |
Enterprise Value | $7.51m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 1.25 |
P/S ratio (TTM) P/S ratio | 12.24 |
P/B ratio (TTM) P/B ratio | 1.36 |
Revenue growth (TTM) Revenue growth | -63.40% |
Revenue (TTM) Revenue | $6.00m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
3 Analysts have issued a Aligos Therapeutics Inc forecast:
3 Analysts have issued a Aligos Therapeutics Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | 6 6 |
63%
63%
|
|
Gross Profit | 3.27 3.27 |
75%
75%
|
|
EBITDA | -92 -92 |
13%
13%
|
EBIT (Operating Income) EBIT | -95 -95 |
12%
12%
|
Net Profit | -77 -77 |
6%
6%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Aligos Therapeutics, Inc. develops targeted, curative therapies for hepatologic diseases and viral infections. It engages in building a pipeline of drug candidates which targets multiple clinically validated mechanisms of action and are designed to achieve functional cure for CHB and become transformative treatment options for COVID-19 and NASH. The company was founded by Lucinda Quan and Lawrence M. Blatt on February 05, 2018 and is headquartered in South San Francisco, CA.
Head office | United States |
CEO | Lawrence Blatt |
Employees | 66 |
Founded | 2018 |
Website | www.aligos.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.